Q1 2025 Pulmonx Corp Earnings Call Transcript
Key Points
- Pulmonx Corp (LUNG) reported a 20% increase in worldwide sales for Q1 2025, reaching $22.5 million, demonstrating strong growth over the previous year.
- The company is executing its 'Acquire, Test, and Treat' strategy effectively, which is expected to support long-term growth and market penetration.
- International revenue saw a significant increase of 39% year-over-year, driven by strong demand in China and other select markets.
- Pulmonx Corp (LUNG) is expanding its field presence by hiring therapy awareness specialists to enhance community physician education and increase patient referrals.
- The company successfully extended the interest-only period on its $37 million term loan by three years, enhancing financial flexibility.
- U.S. revenue growth was moderate at 11%, partly due to challenging prior year comparisons, indicating potential pressure in the domestic market.
- Gross margin decreased to 73% from 75% in the prior year, influenced by a shift in geographic revenue mix.
- Operating expenses increased by 8% year-over-year, driven by expanded commercial investments and clinical trial expenses.
- The company is facing uncertainties related to global macroeconomic conditions, including tariffs and foreign exchange fluctuations, which could impact future performance.
- Despite positive initiatives, Pulmonx Corp (LUNG) did not raise its full-year revenue guidance, citing caution due to the uncertain global economic environment.
Ladies and gentlemen, thank you for standing by, and welcome to Pulmonx first quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to turn the conference over to Laine Morgan, Investor Relations. Please go ahead.
Good afternoon, and thank you for participating in today's call. Joining me from Pulmonx are Steve Williamson, President and Chief Executive Officer; and Mehul Joshi, Chief Financial Officer. Earlier today, Pulmonx issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is available on Pulmonx's website. Before we begin, I'd like to remind you that management will make statements during the call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Any statements contained in this call that relate
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
